BRD2 and fungal keratitis: Another trial randomized one hundred eleven patients with moderate fungal keratitis into four groups (topical 5% NAT alone, topical 5% NAT with CXL, topical 0.15% AMB alone, and topical 0.15% AMB with CXL) [48].